DXCM investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false ...
The complaints allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 ...
On March 7, 2025, DexCom disclosed in a filing with the U.S. Securities and Exchange Commission (“SEC”), that, three days earlier, it had received a warning letter from the U.S. Food and Drug ...
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) investors of an ...
What Is The Lawsuit About? The lawsuit has been filed on behalf of investors who purchased securities during the period of July 26, 2024 through September 17, 2025, inclusive (“the Class Period”). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback